Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en Dlabéticos tipo Dos) study

Journal of Hypertension

Volumn 22, Issue 1, 2004, Pages 217-222

  Ruilope, Luis M ^a   Usan, Luis ^b   Segura, Julián ^a   Bakris, George L ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b ABBOTT LABORATORIES   (Spain)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Combination therapy; High normal blood pressure; Hypertension; Trandolapril; Type 2 diabetes; Verapamil

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANDOLAPRIL; VERAPAMIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSPEPSIA; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 1442274626     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200401000-00032     Document Type: Article

References (26)

1. Hypertension and Diabetic Study (HDS). Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11:309-317.
2. Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ, et al. Prevalence of diabetic complications in relation to risk factors. Diabetes 1986; 35:1332-1339.
3. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
4. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged difference in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
5. Neaton JD, Wentworth D. Serum cholesterol blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152:56-64.
6. Vasan RS, Larson MG, Leip EP, Evans JD, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. Framingham Heart Study. N Engl J Med 2001; 345:1291-1297.
7. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
8. Stamler J, Vaccaro O, Neaton JD, Wenworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
9. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289:2560-2572.
10. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36:646-661.
11. Anonymous. Summary of revisions for the 2003 Clinical Practice Recommendations. Diabetes Care 2003; 26(suppl 1):S3-S147.
12. Oliveira SA, Lapuerta P, McCarthy BD, Litalien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162:413-420.
13. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a metaanalysis. Lancet 2001; 358:1305-1315.
14. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Trialist Collaboration. Lancet 2001; 356:1955-1964.
15. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials. J Hypertens 2002; 20:2099-2110.
16. Garg J, Bakris GL. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetics. Curr Hypertens Reports 2002; 4:185-190.
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
18. Guidelines Committee. The 2003 European Society of Hypertension/European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
19. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. For the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
20. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
21. Bakris GL, Weir M. Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (in press).
22. Waeber B, Brunner HR. Combination antihypertensive therapy: does it have a role in rational therapy. Am J Hypertens 1997; 10:131S-137S.
23. Muisjsers RB, Curran MP, Perry CM. Fixed combination trandolapril/ verapamil sustained release: a review of its use in essential hypertension. Drugs 2002; 62:2541-2569.
24. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combinations versus monotherapy in hypertension: a meta-analysis evaluation. J Hum Hypertens 1999; 13:477-483.
25. Ruilope LM, de la Sierra A, Moreno E, Fernandex R, Garrido J, del la Figuera M, et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. J Hypertens 1999; 17:1917-1923.
26. Fernandez R, Puig JG, Rodriguez-Perez JC, Garrido J, Redȯn J, on behalf of the TRAVEND Study Group. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised double-blind study. J Hum Hypertens 2001; 15:849-856.